1、2025Pharma Services and TechnologyMarket Update2Momentum across pharma services and technology businesses has picked up,and the broader life sciences sector has continued to strengthen in 2025,building on the uptick in leading indicators that characterized the back half of 2024.2025s activity has be

2、en fueled by sustained R&D spend,a strong outlook for future drug approvals,and growing demand for specialized outsourced capabilities.Despite broader macro uncertainties,which have contributed to a higher degree of effort and extended transaction timelines for liquidity events,overall appetite from

3、 private equity and strategic buyers has seen an uptick year-to-date.2025 is shaping up to be a year of resilient growth and meaningful strategic opportunity across the sector.The pharma services and technology sector,broadly defined as the market of outsourced service providers enabling life scienc

4、es companies to discover,research,manufacture,and commercialize novel therapies,continues to expand as the increasing complexity of innovative products,growing use of real-world data and AI-enabled tools,and heightened pressure to accelerate timelines drive sustained demand for specialized,end-to-en

5、d outsourced solutions.2025 has seen renewed momentum across both pharma and biotech,with growth rebounding following reduced vendor spend and a challenging approval environment over the past few years.While the new administration has introduced a degree of policy uncertainty across the pharma servi

6、ces and technology landscape,driven by the U.S.Department of Health and Human Services(HHS)RIFs,scrutiny of direct-to-consumer advertising,most-favored-nation pricing reforms,and pharmaceutical tariffs,among others,the sector has proven highly resilient.Key underlying drivers,including elevated R&D